First Time Loading...

Sanofi SA
NASDAQ:SNY

Watchlist Manager
Sanofi SA Logo
Sanofi SA
NASDAQ:SNY
Watchlist
Price: 49.25 USD 5.66% Market Closed
Updated: Apr 25, 2024

Intrinsic Value

Sanofi engages in the research, production, and distribution of pharmaceutical products. [ Read More ]

The intrinsic value of one SNY stock under the Base Case scenario is 70.42 USD. Compared to the current market price of 49.25 USD, Sanofi SA is Undervalued by 30%.

Key Points:
SNY Intrinsic Value
Base Case
70.42 USD
Undervaluation 30%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation Backtest
Sanofi SA

Backtest Intrinsic Value
Dive into the past to invest in the future

Run backtest to discover the historical profit from buying and selling SNY stocks based on their intrinsic value.

Analyze the historical link between intrinsic value and market price to make more informed investment decisions.

Run Backtest
Settings
Valuation Methods
Buy/Sell Thresholds
Buy When:
%
Sell When:
%
B
S
Run Backtest
How does it work?

Fundamental Analysis

Beta
Ask me anything about
Sanofi SA

Provide an overview of the primary business activities
of Sanofi SA.

What unique competitive advantages
does Sanofi SA hold over its rivals?

What risks and challenges
does Sanofi SA face in the near future?

Summarize the latest earnings call
of Sanofi SA.

What significant events have occurred
in Sanofi SA over the past months?

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for Sanofi SA.

Provide P/S
for Sanofi SA.

Provide P/E
for Sanofi SA.

Provide P/OCF
for Sanofi SA.

Provide P/FCFE
for Sanofi SA.

Provide P/B
for Sanofi SA.

Provide EV/S
for Sanofi SA.

Provide EV/GP
for Sanofi SA.

Provide EV/EBITDA
for Sanofi SA.

Provide EV/EBIT
for Sanofi SA.

Provide EV/OCF
for Sanofi SA.

Provide EV/FCFF
for Sanofi SA.

Provide EV/IC
for Sanofi SA.

Show me price targets
for Sanofi SA made by professional analysts.

What are the Revenue projections
for Sanofi SA?

How accurate were the past Revenue estimates
for Sanofi SA?

What are the Net Income projections
for Sanofi SA?

How accurate were the past Net Income estimates
for Sanofi SA?

What are the EPS projections
for Sanofi SA?

How accurate were the past EPS estimates
for Sanofi SA?

What are the EBIT projections
for Sanofi SA?

How accurate were the past EBIT estimates
for Sanofi SA?

Compare the revenue forecasts
for Sanofi SA with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of Sanofi SA and its key competitors using the latest financial data.

Compare historical revenue growth rates
of Sanofi SA against its competitors.

Analyze the profit margins
(gross, operating, and net) of Sanofi SA compared to its peers.

Compare the P/E ratios
of Sanofi SA against its peers.

Discuss the investment returns and shareholder value creation
comparing Sanofi SA with its peers.

Analyze the financial leverage
of Sanofi SA compared to its main competitors.

Show all profitability ratios
for Sanofi SA.

Provide ROE
for Sanofi SA.

Provide ROA
for Sanofi SA.

Provide ROIC
for Sanofi SA.

Provide ROCE
for Sanofi SA.

Provide Gross Margin
for Sanofi SA.

Provide Operating Margin
for Sanofi SA.

Provide Net Margin
for Sanofi SA.

Provide FCF Margin
for Sanofi SA.

Show all solvency ratios
for Sanofi SA.

Provide D/E Ratio
for Sanofi SA.

Provide D/A Ratio
for Sanofi SA.

Provide Interest Coverage Ratio
for Sanofi SA.

Provide Altman Z-Score Ratio
for Sanofi SA.

Provide Quick Ratio
for Sanofi SA.

Provide Current Ratio
for Sanofi SA.

Provide Cash Ratio
for Sanofi SA.

What is the historical Revenue growth
over the last 5 years for Sanofi SA?

What is the historical Net Income growth
over the last 5 years for Sanofi SA?

What is the current Free Cash Flow
of Sanofi SA?

Discuss the annual earnings per share (EPS)
trend over the past five years for Sanofi SA.

Financials

Balance Sheet Decomposition
Sanofi SA

Current Assets 30.7B
Cash & Short-Term Investments 8.7B
Receivables 391m
Other Current Assets 21.6B
Non-Current Assets 95.7B
Long-Term Investments 10.1B
PP&E 11.8B
Intangibles 73.6B
Other Non-Current Assets 203m
Current Liabilities 24B
Accounts Payable 20.9B
Other Current Liabilities 3.1B
Non-Current Liabilities 28.3B
Long-Term Debt 16.1B
Other Non-Current Liabilities 12.2B
Efficiency

Earnings Waterfall
Sanofi SA

Revenue
46.4B EUR
Cost of Revenue
-14.2B EUR
Gross Profit
32.2B EUR
Operating Expenses
-21.8B EUR
Operating Income
10.4B EUR
Other Expenses
-5B EUR
Net Income
5.4B EUR

Free Cash Flow Analysis
Sanofi SA

Last Value
3-Years Average
FCF Margin
Conversion Rate
History
Components
Chart
Table
Fundamental Scores

SNY Profitability Score
Profitability Due Diligence

Sanofi SA's profitability score is 58/100. The higher the profitability score, the more profitable the company is.

58/100
Profitability
Score

Sanofi SA's profitability score is 58/100. The higher the profitability score, the more profitable the company is.

SNY Solvency Score
Solvency Due Diligence

Sanofi SA's solvency score is 57/100. The higher the solvency score, the more solvent the company is.

Low D/E
Long-Term Solvency
Short-Term Solvency
Positive Net Debt
57/100
Solvency
Score

Sanofi SA's solvency score is 57/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

SNY Price Targets Summary
Sanofi SA

Wall Street analysts forecast SNY stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for SNY is 56.18 USD with a low forecast of 30.22 USD and a high forecast of 70.13 USD.

Lowest
Price Target
30.22 USD
39% Downside
Average
Price Target
56.18 USD
14% Upside
Highest
Price Target
70.13 USD
42% Upside
View Analyst Estimates
View Analyst Estimates

Competitive Landscape

Shareholder Return

SAN Price
Sanofi SA

1M 1M
+2%
6M 6M
-9%
1Y 1Y
-12%
3Y 3Y
+16%
5Y 5Y
+45%
10Y 10Y
+70%
Annual Price Range
91.62
52w Low
81.44
52w High
104.62
Price Metrics
Average Annual Return 10.66%
Standard Deviation of Annual Returns 15.75%
Max Drawdown -22%
Shares Statistics
Market Capitalization 114.9B EUR
Shares Outstanding 1 248 230 016
Percentage of Shares Shorted
N/A

SAN Return Decomposition
Main factors of price return

What is price return decomposition?

SNY News

Other Videos

Last Important Events
Sanofi SA

Significant happenings or occurrences that are of interest to investors. These could be company-specific developments or market-wide shifts.

All
Positive
Negative

Sentiment Analysis
Sanofi SA

Today
Last 7 Days 7D
Last 30 Days 30D
Last 90 Days 90D

Company Profile

Sanofi SA Logo
Sanofi SA

Country

France

Industry

Pharmaceuticals

Market Cap

114.9B USD

Dividend Yield

4.04%

Description

Sanofi engages in the research, production, and distribution of pharmaceutical products. The company is headquartered in Paris, Ile-De-France and currently employs 95,442 full-time employees. The company went IPO on 2002-07-01. The firm focuses on patient needs and engages in the research, development, manufacture, and marketing of therapeutic solutions. Its three operating segments are: Pharmaceuticals, Consumer Healthcare (CHC), and Vaccines. The Pharmaceuticals includes: Immunology, Multiple Sclerosis / Neurology, Oncology, Rare Diseases, Rare Blood Disorders, Cardiovascular, Diabetes, Established Prescription Products. The Vaccines segment comprises, for all geographical territories, the commercial operations of Sanofi Pasteur, together with research, development, and production activities dedicated to vaccines. The CHC segment comprises the commercial operations for Sanofi’s Consumer Healthcare products, together with research, development and production activities dedicated to those products. The Company’s products developed in collaboration or franchise include Dupixent, Aubagio, Lemtrada, Cerezyme, Lumizyme, Jevtana, Fabrazyme, among others.

Contact

ILE-DE-FRANCE
Paris
54 Rue la Boetie
+33153774000.0
https://www.sanofi.com/

IPO

2002-07-01

Employees

95 442

Officers

CEO & Director
Mr. Paul Hudson
Executive VP & CFO
Mr. Jean-Baptiste Chasseloup de Chatillon
Executive VP & Head of Business Operations
Ms. Madeleine Roach
Principal Accounting Officer and Vice President of Corporate Accounting
Mr. Laurent Gilhodes
Chief Science Officer of Consumer Health Care
Dr. Josephine Fubara
Head of Investor Relations
Eva Schaefer-Jansen
Show More
Global Compliance Officer & VP
Mr. Dante Beccaria
Executive VP & General Counsel
Mr. Roy Papatheodorou
Head of Communications
Mr. Josep Catlla
Senior Vice President of Global Diabetes and Senior Vice President of Global Marketing
Mr. Pierre Chancel
Show Less

See Also

Discover More
What is the Intrinsic Value of one SNY stock?

The intrinsic value of one SNY stock under the Base Case scenario is 70.42 USD.

Is SNY stock undervalued or overvalued?

Compared to the current market price of 49.25 USD, Sanofi SA is Undervalued by 30%.